[埃隆-马斯克的言论对拉齐奥地区使用塞马鲁肽的影响:一项时间序列分析研究。]

Q3 Medicine Recenti progressi in medicina Pub Date : 2024-12-01 DOI:10.1701/4392.43917
Valeria Belleudi, Sara Lopes, Antonio Addis
{"title":"[埃隆-马斯克的言论对拉齐奥地区使用塞马鲁肽的影响:一项时间序列分析研究。]","authors":"Valeria Belleudi, Sara Lopes, Antonio Addis","doi":"10.1701/4392.43917","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In recent times, TikTok 'weight loss influencers' have been promoting the use of GLP-1 receptor agonist drugs, with particular emphasis on semaglutide. The popularity of this class of drugs has been amplified by the statements of Elon Musk, who publicly declared in October 2022 that he had lost weight thanks to Wegovy, a semaglutide-based medication launched in the US. In Italy, GLP-1 receptor agonists are mainly indicated for the treatment of type 2 diabetes, but in certain cases they can be prescribed off-label for obesity and overweight. The aim of this study is to assess the impact of Elon Musk's statements on the use of semaglutide within Regional Health Service of the Lazio Region.</p><p><strong>Methods: </strong>Dispensations of GLP-1 receptor agonist drugs (ATC: A10BJ) within Regional Health Service in the Lazio Region between January 2022 and March 2023 were analysed, identifying those related to semaglutide (ATC: A10BJ06). Monthly time series data on new users (with a 1-year washout period) of semaglutide and other GLP-1 drugs were compared to identify any changes after October 2022. In addition, the proportion of patients for whom it was possible to verify the indication of diabetes through health administrative data was examined.</p><p><strong>Results: </strong>Analysis of the monthly trends for the entire class of GLP-1 receptor agonist drugs showed no difference in the monthly average of incident users between the pre and post Elon Musk statements. However, an increase in incident users was observed for semaglutide (monthly average: from 872 pre to 1,380 post) at the expense of the use of other drugs in the same class (monthly average: from 711 pre to 208 post). The proportion of semaglutide users for whom diabetes could not be confirmed remained stable over time at approximately 9.5%.</p><p><strong>Conclusions: </strong>Elon Musk's statements seem to have had an impact on the use of semaglutide among patients in the Lazio region. Further analyses are necessary to carefully assess the presence of possible other factors influencing the preference for semaglutide over other GLP-1 receptor agonists.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"115 12","pages":"593-598"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.]\",\"authors\":\"Valeria Belleudi, Sara Lopes, Antonio Addis\",\"doi\":\"10.1701/4392.43917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In recent times, TikTok 'weight loss influencers' have been promoting the use of GLP-1 receptor agonist drugs, with particular emphasis on semaglutide. The popularity of this class of drugs has been amplified by the statements of Elon Musk, who publicly declared in October 2022 that he had lost weight thanks to Wegovy, a semaglutide-based medication launched in the US. In Italy, GLP-1 receptor agonists are mainly indicated for the treatment of type 2 diabetes, but in certain cases they can be prescribed off-label for obesity and overweight. The aim of this study is to assess the impact of Elon Musk's statements on the use of semaglutide within Regional Health Service of the Lazio Region.</p><p><strong>Methods: </strong>Dispensations of GLP-1 receptor agonist drugs (ATC: A10BJ) within Regional Health Service in the Lazio Region between January 2022 and March 2023 were analysed, identifying those related to semaglutide (ATC: A10BJ06). Monthly time series data on new users (with a 1-year washout period) of semaglutide and other GLP-1 drugs were compared to identify any changes after October 2022. In addition, the proportion of patients for whom it was possible to verify the indication of diabetes through health administrative data was examined.</p><p><strong>Results: </strong>Analysis of the monthly trends for the entire class of GLP-1 receptor agonist drugs showed no difference in the monthly average of incident users between the pre and post Elon Musk statements. However, an increase in incident users was observed for semaglutide (monthly average: from 872 pre to 1,380 post) at the expense of the use of other drugs in the same class (monthly average: from 711 pre to 208 post). The proportion of semaglutide users for whom diabetes could not be confirmed remained stable over time at approximately 9.5%.</p><p><strong>Conclusions: </strong>Elon Musk's statements seem to have had an impact on the use of semaglutide among patients in the Lazio region. Further analyses are necessary to carefully assess the presence of possible other factors influencing the preference for semaglutide over other GLP-1 receptor agonists.</p>\",\"PeriodicalId\":20887,\"journal\":{\"name\":\"Recenti progressi in medicina\",\"volume\":\"115 12\",\"pages\":\"593-598\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recenti progressi in medicina\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1701/4392.43917\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4392.43917","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.]

Introduction: In recent times, TikTok 'weight loss influencers' have been promoting the use of GLP-1 receptor agonist drugs, with particular emphasis on semaglutide. The popularity of this class of drugs has been amplified by the statements of Elon Musk, who publicly declared in October 2022 that he had lost weight thanks to Wegovy, a semaglutide-based medication launched in the US. In Italy, GLP-1 receptor agonists are mainly indicated for the treatment of type 2 diabetes, but in certain cases they can be prescribed off-label for obesity and overweight. The aim of this study is to assess the impact of Elon Musk's statements on the use of semaglutide within Regional Health Service of the Lazio Region.

Methods: Dispensations of GLP-1 receptor agonist drugs (ATC: A10BJ) within Regional Health Service in the Lazio Region between January 2022 and March 2023 were analysed, identifying those related to semaglutide (ATC: A10BJ06). Monthly time series data on new users (with a 1-year washout period) of semaglutide and other GLP-1 drugs were compared to identify any changes after October 2022. In addition, the proportion of patients for whom it was possible to verify the indication of diabetes through health administrative data was examined.

Results: Analysis of the monthly trends for the entire class of GLP-1 receptor agonist drugs showed no difference in the monthly average of incident users between the pre and post Elon Musk statements. However, an increase in incident users was observed for semaglutide (monthly average: from 872 pre to 1,380 post) at the expense of the use of other drugs in the same class (monthly average: from 711 pre to 208 post). The proportion of semaglutide users for whom diabetes could not be confirmed remained stable over time at approximately 9.5%.

Conclusions: Elon Musk's statements seem to have had an impact on the use of semaglutide among patients in the Lazio region. Further analyses are necessary to carefully assess the presence of possible other factors influencing the preference for semaglutide over other GLP-1 receptor agonists.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Recenti progressi in medicina
Recenti progressi in medicina Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
143
期刊介绍: Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.
期刊最新文献
(Con)fine della salute: restituzione del lavoro di un ambulatorio popolare dai margini della città. [GLP-1 agonists reduce the risk of major cardiovascular events in older patients with type 2 diabetes, and SGLT2 inhibitors prevent hospitalizations for acute heart failure.] [Impact of Elon Musk's statements on the use of semaglutide in the Lazio Region: a time series analysis study.] [Effective treatment for Helicobacter pylori infection in adults: the 2024 American College of Gastroenterology guideline recommendations.] [Patients with heart failure experience fewer hospitalizations and reduced mortality when treated with mineralocorticoid receptor antagonists.]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1